Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia.

Brown WW, Jüppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL.

J Clin Endocrinol Metab. 2009 Jan;94(1):17-20. doi: 10.1210/jc.2008-0220. Epub 2008 Oct 14.

2.

Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia.

Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Jüppner H.

N Engl J Med. 1996 Sep 5;335(10):708-14.

3.

Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.

Onuchic L, Ferraz-de-Souza B, Mendonca BB, Correa PH, Martin RM.

J Clin Endocrinol Metab. 2012 Apr;97(4):1098-103. doi: 10.1210/jc.2011-3082. Epub 2012 Jan 25.

PMID:
22278430
4.

A form of Jansen's metaphyseal chondrodysplasia with limited metabolic and skeletal abnormalities is caused by a novel activating parathyroid hormone (PTH)/PTH-related peptide receptor mutation.

Bastepe M, Raas-Rothschild A, Silver J, Weissman I, Wientroub S, Jüppner H, Gillis D.

J Clin Endocrinol Metab. 2004 Jul;89(7):3595-600.

PMID:
15240651
5.

Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.

Sánchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Pérez Flores I, Vidaurreta M, Valero R, Fernández-Pérez C, Barrientos A.

Transplant Proc. 2012 Nov;44(9):2551-4. doi: 10.1016/j.transproceed.2012.09.070.

PMID:
23146451
6.

The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Calvi LM, Schipani E.

J Endocrinol Invest. 2000 Sep;23(8):545-54. Review.

PMID:
11021773
7.

A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia.

Schipani E, Langman C, Hunzelman J, Le Merrer M, Loke KY, Dillon MJ, Silve C, Jüppner H.

J Clin Endocrinol Metab. 1999 Sep;84(9):3052-7.

PMID:
10487664
8.

Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Weber TJ, Liu S, Indridason OS, Quarles LD.

J Bone Miner Res. 2003 Jul;18(7):1227-34.

9.

Jansen's metaphyseal chondrodysplasia: a disorder due to a PTH/PTHrP receptor gene mutation.

Jüppner H.

Trends Endocrinol Metab. 1996 Jul;7(5):157-62.

PMID:
18406742
10.

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.

Kidney Int. 2006 Feb;69(3):531-7.

11.

Fibroblast growth factor 23 and calcium phosphate homeostasis after pediatric renal transplantation.

van Husen M, Lehnhardt A, Fischer AK, Brinkert F, Loos S, Oh J, Kemper MJ.

Pediatr Transplant. 2012 Aug;16(5):443-50. doi: 10.1111/j.1399-3046.2012.01702.x. Epub 2012 May 4.

PMID:
22554017
12.

FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M.

Am J Physiol Renal Physiol. 2009 Aug;297(2):F282-91. doi: 10.1152/ajprenal.90742.2008. Epub 2009 Jun 10.

13.

Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4.

Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M.

Am J Physiol Renal Physiol. 2011 Aug;301(2):F371-7. doi: 10.1152/ajprenal.00740.2010. Epub 2011 May 11.

14.

Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.

Tomida K, Hamano T, Ichimaru N, Fujii N, Matsui I, Nonomura N, Tsubakihara Y, Rakugi H, Takahara S, Isaka Y.

Bone. 2012 Oct;51(4):729-36. doi: 10.1016/j.bone.2012.06.027. Epub 2012 Jul 14.

PMID:
22796419
16.
17.

Hypophosphatemic rickets in opsismodysplasia.

Zeger MD, Adkins D, Fordham LA, White KE, Schoenau E, Rauch F, Loechner KJ.

J Pediatr Endocrinol Metab. 2007 Jan;20(1):79-86.

PMID:
17315533
18.

Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM.

J Clin Endocrinol Metab. 2010 Nov;95(11):E352-7. doi: 10.1210/jc.2010-0589. Epub 2010 Aug 4.

19.

FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG.

J Clin Endocrinol Metab. 2009 Jul;94(7):2332-7. doi: 10.1210/jc.2008-2396. Epub 2009 Apr 14.

PMID:
19366850
20.

Vitamin D and type II sodium-dependent phosphate cotransporters.

Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K.

Contrib Nephrol. 2013;180:86-97. doi: 10.1159/000346786. Epub 2013 May 6. Review.

PMID:
23652552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk